"Remdesivir"

The antiviral drug remdesivir can help keep unvaccinated people at risk of severe covid-19 out of the hospital, according to a new study that found the treatment reduced hospitalization and death by 87% when given soon after diagnosis.

PTT’s subsidiary Innobic (Asia), a joint venture with Taiwanese pharmaceutical firm Lotus, is planning to import 2,000 bottles of Remdesivir by the end of this month.

Shouldn't a medicine like Remdesivir, which has proved to be life-saving in certain cases of Covid-19, be made available to all those who need it without delay?

The Food and Drug Administration approved Gilead Sciences Inc.'s antiviral therapy remdesivir on Thursday, making it the first drug to obtain formal clearance for treating the coronavirus.

Researchers are currently testing all 21 compounds in small animal models and “mini lungs,” or lung organoids, that mimic the human tissue.

Gilead Sciences, the maker of the first covid-19 treatment found to have worked in clinical trials, said it will charge U.S. hospitals $3,120 for the typical patient with private insurance.

The drug that buoyed expectations for a coronavirus treatment and drew international attention for Gilead Sciences, remdesivir, started as a reject, an also-ran in the search for antiviral drugs. Its path to relevance did not begin until Robert Jordan cleared it.

Covid-19 is a new disease caused by a virus, so there is no specific treatment, Dr Yong Poovorawan, an expert virologist at Chulalongkorn University, said while advocating the use of plasma to treat patients.

The Stock Exchange of Thailand (SET) Index closed at 1,239.24 today (April 17), up 39.09 points or 3.26 per cent.

The Stock Exchange of Thailand (SET) Index rebounded by 26.85 points, or 2.24 per cent, to 1,227.00 in morning trade on Friday (April 17).